Treatment satisfaction in cystic fibrosis: Early patient experience with tobramycin inhalation powder

11Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Background: This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder–inhaled antibiotic for Pseudomonas aeruginosa infection. Methods: CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction. Results: Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP’s administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regression R-squared: 0.54). Conclusion: Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness.

Cite

CITATION STYLE

APA

Greenberg, J., Palmer, J. B., Chan, W. W., Correia, C. E., Whalley, D., Shannon, P., & Sawicki, G. S. (2016). Treatment satisfaction in cystic fibrosis: Early patient experience with tobramycin inhalation powder. Patient Preference and Adherence, 10, 2163–2169. https://doi.org/10.2147/PPA.S102234

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free